Profile
Chulho Park is the founder of Oncotelic, Inc. (founded in 2015) where he holds the title of Chief Technology Officer.
He was also the founder of Mabprex, Inc. (founded in 2010) where he held the title of Chief Executive Officer until 2018.
Dr. Park's former jobs include being the Chief Technology Officer at Oncotelic Therapeutics, Inc. from 2019 to 2021 and being the President-Pharmaceutical Development at IgDraSol, Inc. in 2013.
Chulho Park active positions
| Companies | Position | Start |
|---|---|---|
Oncotelic, Inc.
 Oncotelic, Inc. BiotechnologyHealth Technology Oncotelic, Inc. develops a therapeutic platform for cancer treatments. It conducts registration trials for multiple cancer indications including pancreatic, melanoma, and glioblastoma. The company was founded by Vuong Trieu and Chulho Park and is headquartered in Agoura Hills, CA. | Founder | 2014-12-31 |
Former positions of Chulho Park
| Companies | Position | End |
|---|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-06-30 |
| Mabprex, Inc. | Chief Executive Officer | 2017-12-31 |
IgDraSol, Inc.
 IgDraSol, Inc. Pharmaceuticals: MajorHealth Technology Part of Cambridge Equities LP, IgDraSol, Inc. is a private company that manufactures cancer therapeutics. The company is based in Fountain Valley, CA. The company was founded by Larn Hwang, Vuong Trieu. IgDraSol was acquired by NantPharma LLC from Sorrento Therapeutics, Inc. on May 15, 2015 for $1,290 million. | Corporate Officer/Principal | 2013-08-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
IgDraSol, Inc.
IgDraSol, Inc. Pharmaceuticals: MajorHealth Technology Part of Cambridge Equities LP, IgDraSol, Inc. is a private company that manufactures cancer therapeutics. The company is based in Fountain Valley, CA. The company was founded by Larn Hwang, Vuong Trieu. IgDraSol was acquired by NantPharma LLC from Sorrento Therapeutics, Inc. on May 15, 2015 for $1,290 million. | Health Technology |
Oncotelic, Inc.
Oncotelic, Inc. BiotechnologyHealth Technology Oncotelic, Inc. develops a therapeutic platform for cancer treatments. It conducts registration trials for multiple cancer indications including pancreatic, melanoma, and glioblastoma. The company was founded by Vuong Trieu and Chulho Park and is headquartered in Agoura Hills, CA. | Health Technology |
| Mabprex, Inc. |
- Stock Market
- Insiders
- Chulho Park